Takahashi K - Search Results

1

A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor.

Suzuki K, Morokata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, Shimizu Y. Suzuki K, et al. Among authors: takahashi k. Eur J Pharmacol. 2007 Jun 1;563(1-3):224-32. doi: 10.1016/j.ejphar.2007.01.074. Epub 2007 Feb 8. Eur J Pharmacol. 2007. PMID: 17336292

2

A novel, selective, and orally available antagonist for CC chemokine receptor 3.

Morokata T, Suzuki K, Masunaga Y, Taguchi K, Morihira K, Sato I, Fujii M, Takizawa S, Torii Y, Yamamoto N, Kaneko M, Yamada T, Takahashi K, Shimizu Y. Morokata T, et al. Among authors: takahashi k. J Pharmacol Exp Ther. 2006 Apr;317(1):244-50. doi: 10.1124/jpet.105.097048. Epub 2005 Dec 9. J Pharmacol Exp Ther. 2006. PMID: 16339911

3

In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031.

Suzuki K, Morokata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, Shimizu Y. Suzuki K, et al. Among authors: takahashi k. Biochem Biophys Res Commun. 2006 Jan 27;339(4):1217-23. doi: 10.1016/j.bbrc.2005.11.141. Epub 2005 Dec 5. Biochem Biophys Res Commun. 2006. PMID: 16343433

4

Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs.

Kubo S, Kobayashi M, Iwata M, Takahashi K, Miyata K, Shimizu Y. Kubo S, et al. Among authors: takahashi k. Eur J Pharmacol. 2011 May 20;659(1):79-84. doi: 10.1016/j.ejphar.2011.02.042. Epub 2011 Mar 5. Eur J Pharmacol. 2011. PMID: 21385578

5

Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation.

Kobayashi M, Kubo S, Shiraki K, Iwata M, Hirano Y, Ohtsu Y, Takahashi K, Shimizu Y. Kobayashi M, et al. Among authors: takahashi k. Pharmacology. 2012;90(3-4):223-32. doi: 10.1159/000342380. Epub 2012 Sep 13. Pharmacology. 2012. PMID: 23038661

6

Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.

Kubo S, Kobayashi M, Iwata M, Miyata K, Takahashi K, Shimizu Y. Kubo S, et al. Among authors: takahashi k. Int Immunopharmacol. 2012 Jan;12(1):59-63. doi: 10.1016/j.intimp.2011.10.011. Epub 2011 Oct 29. Int Immunopharmacol. 2012. PMID: 22041526

7

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.

Kobayashi M, Kubo S, Iwata M, Ohtsu Y, Takahashi K, Shimizu Y. Kobayashi M, et al. Among authors: takahashi k. Int Immunopharmacol. 2011 Jun;11(6):732-9. doi: 10.1016/j.intimp.2011.01.023. Epub 2011 Feb 23. Int Immunopharmacol. 2011. PMID: 21315169

8

Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.

Kobayashi M, Kubo S, Hirano Y, Kobayashi S, Takahashi K, Shimizu Y. Kobayashi M, et al. Among authors: takahashi k. Int Immunopharmacol. 2012 Jan;12(1):50-8. doi: 10.1016/j.intimp.2011.10.008. Epub 2011 Oct 25. Int Immunopharmacol. 2012. PMID: 22036845

9

Cytokine and chemokine expression in cigarette smoke-induced lung injury in guinea pigs.

Kubo S, Kobayashi M, Masunaga Y, Ishii H, Hirano Y, Takahashi K, Shimizu Y. Kubo S, et al. Among authors: takahashi k. Eur Respir J. 2005 Dec;26(6):993-1001. doi: 10.1183/09031936.05.00042405. Eur Respir J. 2005. PMID: 16319327 Free article.

10

Comparison of incadronate and alfacalcidol on increased bone turnover caused by ovariectomy in rats.

Teramura K, Fukushima S, Nozaki K, Kokubo S, Takahashi K. Teramura K, et al. Among authors: takahashi k. Eur J Pharmacol. 2002 Aug 2;449(1-2):191-6. doi: 10.1016/s0014-2999(02)01979-9. Eur J Pharmacol. 2002. PMID: 12163124

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,299 results

Search Page

Filters